Scholarlink

Background <p>Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are increasingly prescribed for patients with type 2 diabetes mellitus (T2DM) and obesity undergoing metabolic and bariatric surgery (MBS). This study evaluated the association between preoperative GLP-1-RAs exposure and the risk of acute kidney injury (AKI) following MBS.</p> Methods <p>This retrospective cohort study utilized the TriNetX Research Network to identify adults with T2DM and a body mass index exceeding 35&#xa0;kg/m² who underwent elective laparoscopic MBS (2010–2024). Patients were stratified by preoperative GLP-1-RAs exposure and matched using propensity score analysis. The primary outcome was the incidence of AKI within 90 days after surgery, and the secondary outcomes included mortality, intensive care unit (ICU) admission, sepsis, and events of postoperative hyperglycemia (i.e., serum glucose &gt; 180&#xa0;mg/dL).</p> Results <p>After propensity score matching, 5,480 patients were included in each cohort. Preoperative GLP-1-RAs exposure was associated with a significantly reduced 90-day AKI risk (1.6% versus 2.3%; hazard ratio [HR]: 0.68, 95% confidence interval [CI] 0.52–0.89, <i>p</i> = 0.005, absolute risk reduction [ARR]:0.73%, number needed to treat [NNT]:137) and 30-day risk (HR: 0.58, <i>p</i> = 0.001). GLP-1-RAs exposure also correlated with a lower risk of postoperative hyperglycemia (24.5% versus 26.6%, HR:0.91, 95% CI: 0.85–0.99, <i>p</i> = 0.013, ARR 2.04%, NNT 49). No significant differences were observed in mortality, ICU admission, or sepsis. Sensitivity analyses confirmed these consistent findings.</p> Conclusion <p>Preoperative GLP-1-RAs exposure was associated with a reduced AKI risk following MBS, with concurrent improvement in perioperative glycemic control. Future randomized controlled studies are required to validate these observational findings and clarify the underlying mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preoperative GLP-1 Receptor Agonists Exposure and Risk of Postoperative Acute Kidney Injury after Metabolic and Bariatric Surgery: A Retrospective Study

  • 期刊论文

  • 发表日期：

    2025年12月17日

查看全文
  • Kuo-Chuan Hung,
  • Li-Chen Chang,
  • Ping-Heng Tan,
  • Chih-Wei Hsu,
  • Yi-Chen Lai,
  • Jheng-Yan Wu,
  • I-Wen Chen

摘要

Background

Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are increasingly prescribed for patients with type 2 diabetes mellitus (T2DM) and obesity undergoing metabolic and bariatric surgery (MBS). This study evaluated the association between preoperative GLP-1-RAs exposure and the risk of acute kidney injury (AKI) following MBS.

Methods

This retrospective cohort study utilized the TriNetX Research Network to identify adults with T2DM and a body mass index exceeding 35 kg/m² who underwent elective laparoscopic MBS (2010–2024). Patients were stratified by preoperative GLP-1-RAs exposure and matched using propensity score analysis. The primary outcome was the incidence of AKI within 90 days after surgery, and the secondary outcomes included mortality, intensive care unit (ICU) admission, sepsis, and events of postoperative hyperglycemia (i.e., serum glucose > 180 mg/dL).

Results

After propensity score matching, 5,480 patients were included in each cohort. Preoperative GLP-1-RAs exposure was associated with a significantly reduced 90-day AKI risk (1.6% versus 2.3%; hazard ratio [HR]: 0.68, 95% confidence interval [CI] 0.52–0.89, p = 0.005, absolute risk reduction [ARR]:0.73%, number needed to treat [NNT]:137) and 30-day risk (HR: 0.58, p = 0.001). GLP-1-RAs exposure also correlated with a lower risk of postoperative hyperglycemia (24.5% versus 26.6%, HR:0.91, 95% CI: 0.85–0.99, p = 0.013, ARR 2.04%, NNT 49). No significant differences were observed in mortality, ICU admission, or sepsis. Sensitivity analyses confirmed these consistent findings.

Conclusion

Preoperative GLP-1-RAs exposure was associated with a reduced AKI risk following MBS, with concurrent improvement in perioperative glycemic control. Future randomized controlled studies are required to validate these observational findings and clarify the underlying mechanisms.